Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

The Lancet ◽  
2015 ◽  
Vol 385 (9983) ◽  
pp. 2153-2161 ◽  
Author(s):  
John J P Kastelein ◽  
Joost Besseling ◽  
Sukrut Shah ◽  
Jean Bergeron ◽  
Gisle Langslet ◽  
...  
Keyword(s):  
Familial Hypercholesterolaemia ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Heterozygous Familial Hypercholesterolaemia

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

2014 ◽  
Vol 2 (6) ◽  
pp. 455-463 ◽  
Author(s):  
Barbara Sjouke ◽  
Gisle Langslet ◽  
Richard Ceska ◽  
Stephen J Nicholls ◽  
Steven E Nissen ◽  
...  
Keyword(s):  
Familial Hypercholesterolaemia ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo

IP 1184. ZX008 (Fenfluramine) in Dravet’s Syndrome: First Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

2018 ◽  
Author(s):  
Tilman Polster ◽  
Lieven Lagae ◽  
Joseph Sullivan ◽  
Ulrich Brandl ◽  
Arne Herting ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
First Results
Sign in / Sign up

Export Citation Format

Share Document